2.490USDMkt Cap: 179.85M USDP/E: —Last update: 2026-05-21
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap179.85M USD
Enterprise Value82.50M USD
Revenue (TTM)—
Gross Profit-104.89M USD
Net Income (TTM)-121.33M USD
Revenue/Share—
Last Price2.490 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees60
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.64
PEG—
EV/EBITDA-0.72
EV/Revenue—
P/S—
P/B2.06
EPS (TTM)-1.85
EPS (Forward)-1.52
52W Range
2.300100% of range2.490
52W High2.490 USD
52W Low2.300 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-172.28%
ROA-98.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-115.54M USD
CapEx (TTM)88.00K USD
FCF Margin—
FCF Yield-37.39%
Net Debt-97.35M USD
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.44
Current Ratio4.55
Quick Ratio4.39
Book Value/Sh1.211 USD
Cash/Share1.778 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)7.400 USD
Target Range4.000 USD – 10.00 USD
# Analysts5
Ownership
Shares Out.72.23M
Float37.01M
Insiders6.67%
Institutions63.99%
Short Interest
Short Ratio4.0d
Short % Float3.33%
Short % Out.2.32%
Shares Short1.68M
Short (prev mo.)1.06M
Technical
SMA 502.603 (-4.3%)
SMA 2002.139 (+16.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)412.87K
Avg Vol (10d)336.50K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—